Close

Brainstem glioma

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview

A brainstem glioma is a cancerous glioma tumor which begins from the brain or spinal cord tissue and typically spread throughout the nervous system. Seventy-five percent of brainstem glioma occurs in children and young adults under the age of twenty, but it can also influence older adults. Brainstem gliomas account for about 10-20% of all brain tumors in children. The cause is still not clear. Any direct genetic link has not been found. The prognosis varies depending on the location and the size of the brainstem glioma.

Signs and symptoms

The common symptoms include but not limited to drooping of the face, double vision or not being able to close the eyelids, headache or headache that gets better after vomiting, nausea and vomiting, weakness and fatigue, seizures and balance problems. In summary, common clinical signs and physical exam performance such as constituting a triad of cranial nerve deficits, long tract signs, and ataxia (of trunk and limbs) are present.

Loading...
Products
Global Services
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.